-effectiveness of adding pertuzumab in neoadjuvant treatment (NeoT) for HER2-positive breast cancer (BC). Methods: Two retrospective … also pertuzumab as NeoT. NeoT was followed by surgery and adjuvant trastuzumab. Micro-costing technique and a bottom …-DHP average total cost/patient was 56,375€, with pertuzumab accounting for 13,978€ (24.79%) and increasing in 15,982€ the average …

-effectiveness of adding pertuzumab in neoadjuvant treatment (NeoT) for HER2-positive breast cancer (BC). Methods: Two retrospective … also pertuzumab as NeoT. NeoT was followed by surgery and adjuvant trastuzumab. Micro-costing technique and a bottom …-DHP average total cost/patient was 56,375€, with pertuzumab accounting for 13,978€ (24.79%) and increasing in 15,982€ the average …

2+ breast cancer. The aim is to assess the cost-effectiveness of adding pertuzumab to the combination of trastuzumab …, the addition of pertuzumab does not result in significantly longer patients' survival. Since the treatment is associated … with higher costs, adding pertuzumab is not considered to be cost-effective; however, this could be due to relatively short …

2+ breast cancer. The aim is to assess the cost-effectiveness of adding pertuzumab to the combination of trastuzumab …, the addition of pertuzumab does not result in significantly longer patients' survival. Since the treatment is associated … with higher costs, adding pertuzumab is not considered to be cost-effective; however, this could be due to relatively short …